NCT01395316View on ClinicalTrials.gov

Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

October 31, 2015

Study Completion Date

July 31, 2017

Conditions
Multiple Sclerosis
Interventions
DRUG

Alemtuzumab

10 mg/ml alemtuzumab intravenous infusion, sterile clear, colorless solution. dosage: 2 cycles. Month 0 dosed over 5 consecutive days: month 12 dosed over 3 consecutive days.

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

University of Chicago

OTHER

NCT01395316 - Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis | Biotech Hunter | Biotech Hunter